AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30021584 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat flexible shoes
Number of subjects: 164
Study 30021584 — intervention group
Group type: COMPARATOR
Intervention: Stable supportive shoes
Number of subjects: 164
Study 28601972 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 8-mg QDx3d QW plus paclitaxel 80 mg/m2
Number of subjects: 67
Study 28601972 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 10-mg QDx3d QW plus paclitaxel 80 mg/m2
Number of subjects: 67
Study 28601972 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 with/without trastuzumab
Number of subjects: 67
Study 28601972 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study 25910632 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided care and viral PCR testing
Number of subjects: 300
Study 25910632 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 24192332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-containing triple-ARV prophylaxis continued during breastfeeding up to 6 months
Number of subjects: 1070
Study 24192332 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine during pregnancy plus single-dose nevirapine (sd-NVP) at labour
Number of subjects: 1070
Study 21932025 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) plus regional hyperthermia (HT)
Number of subjects: 68
Study 21932025 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 68
Study 18176972 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/d plus 5-ASA 2 g/d daily for 4 weeks
Number of subjects: 42
Study 18176972 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA 2 g/d alone for 4 weeks
Number of subjects: 42
Study 16646033 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered at weeks 0, 2, 6, and then every 6 weeks thereafter
Number of subjects: 266
Study 16646033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 12683261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with a combination of AA (Arachidonic Acid) and DHA (Docosahexaenoic Acid) and antioxidants (vitamins E and C)
Number of subjects: 0
Study 12683261 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic treatment
Number of subjects: 0
Study 10979928 — intervention group
Group type: EXPERIMENTAL
Intervention: PMP-resistant Staphylococcus aureus strains
Number of subjects: 58
Study 10979928 — intervention group
Group type: COMPARATOR
Intervention: PMP-susceptible Staphylococcus aureus strains
Number of subjects: 58
Study 8634416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HIDAC-3-7) 3 g/m2 12 hourly on days 1, 3, 5, and 7 for 8 doses, with daunorubicin 50 mg/m2 days 1 to 3, etoposide 75 mg/m2 days 1 to 7.
Number of subjects: 301
Study 8634416 — intervention group
Group type: COMPARATOR
Intervention: Standard dose cytarabine (7-3-7) 100 mg/m2 continuous intravenous infusion for 7 days, with daunorubicin and etoposide at the same dose and schedule as HIDAC-3-7.
Number of subjects: 301
Study 8634416 — intervention group
Group type: EXPERIMENTAL
Intervention: HIDAC-3-7
Number of subjects: 301
Study 8634416 — intervention group
Group type: COMPARATOR
Intervention: 7-3-7
Number of subjects: 301
Study 8634416 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation treatment (5-2-5)
Number of subjects: 301
Study 1458044 — intervention group
Group type: EXPERIMENTAL
Intervention: Processes of change in smoking cessation for cardiac patients
Number of subjects: 213
Study 1458044 — intervention group
Group type: COMPARATOR
Intervention: Processes of change in smoking cessation for nonmedical smokers
Number of subjects: 213
Study 6202571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg daily, 200 mg every 8 hours)
Number of subjects: 26
Study 6202571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6202571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg daily)
Number of subjects: 26
Study 6202571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 26
Study 30777584 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence (assessed by a blind clinician)
Number of subjects: 34
Study 30777584 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence (assessed by a nonblind clinician)
Number of subjects: 34
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF for 12 weeks
Number of subjects: 89
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF + RBV for 12 weeks
Number of subjects: 89
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF for 24 weeks
Number of subjects: 89
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF + RBV for 12 weeks (A5348 study)
Number of subjects: 89
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF for 24 weeks (A5348 study)
Number of subjects: 89
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 89
Study 29091342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious AEs
Number of subjects: 89
Study 26856211 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual stroke unit diagnostic procedures plus standardized and centrally analyzed Holter ECG recording for up to 7 days in hospital
Number of subjects: 3470
Study 26856211 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke unit diagnostic procedures for detection of AF
Number of subjects: 3470
Study 24530788 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (30 g alcohol/d)
Number of subjects: 33
Study 24530788 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer (equivalent polyphenols)
Number of subjects: 33
Study 24530788 — intervention group
Group type: COMPARATOR
Intervention: Gin (30 g alcohol/d)
Number of subjects: 33
Study 22550117 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-7 (rhIL-7) at a dose of 20 µg/kg
Number of subjects: 26
Study 22550117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20403021 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 12
Study 20403021 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 12
Study 20403021 — intervention group
Group type: COMPARATOR
Intervention: Heroin
Number of subjects: 12
Study 17852016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential trial design
Number of subjects: 0
Study 17852016 — intervention group
Group type: COMPARATOR
Intervention: Classical trial design
Number of subjects: 0
Study 16119665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracosurgical patients
Number of subjects: 100
Study 16119665 — intervention group
Group type: COMPARATOR
Intervention: General surgical patients
Number of subjects: 100
Study 16119665 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care ability evaluation
Number of subjects: 100
Study 12105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of MDMA (3,4-methylenedioxymethamphetamine)
Number of subjects: 0
Study 12105117 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA in poor metabolizers
Number of subjects: 0
Study 12105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational MDMA use over a 2-year observation period
Number of subjects: 0
Study 12105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal values of lymphocyte subsets in MDMA users
Number of subjects: 0
Study 11816697 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1RN-VNTR genotype
Number of subjects: 770
Study 11816697 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and smoking-matched)
Number of subjects: 770
Study 9260077 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated cola (33 mg/8 oz)
Number of subjects: 24
Study 9260077 — intervention group
Group type: COMPARATOR
Intervention: Placebo cola (noncaffeinated)
Number of subjects: 24
Study 8365592 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminutive adenoma group (66 subjects)
Number of subjects: 162
Study 8365592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed hyperplastic-adenomatous polyp group (12 subjects)
Number of subjects: 162
Study 8365592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperplastic polyp group (42 subjects)
Number of subjects: 162
Study 8365592 — intervention group
Group type: COMPARATOR
Intervention: Control group (42 subjects)
Number of subjects: 162
Study 3812057 — intervention group
Group type: EXPERIMENTAL
Intervention: basic treatment plus significant other support condition
Number of subjects: 29
Study 3812057 — intervention group
Group type: COMPARATOR
Intervention: basic smoking control program
Number of subjects: 29
Study 29870867 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT in-person
Number of subjects: 120
Study 29870867 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT remote
Number of subjects: 120
Study 29870867 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT
Number of subjects: 120
Study 29870867 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26746907 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion control shoes
Number of subjects: 372
Study 26746907 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion control shoes (in runners with pronated feet)
Number of subjects: 372
Study 26746907 — intervention group
Group type: COMPARATOR
Intervention: Standard shoes (in runners with pronated feet)
Number of subjects: 372
Study 26746907 — intervention group
Group type: COMPARATOR
Intervention: Standard shoes (in runners with neutral feet)
Number of subjects: 372
Study 26746907 — intervention group
Group type: COMPARATOR
Intervention: Standard shoes (in runners with supinated feet)
Number of subjects: 372
Study 25710636 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (submaximal invasive cardiopulmonary exercise test)
Number of subjects: 17
Study 25710636 — intervention group
Group type: COMPARATOR
Intervention: Control (submaximal invasive cardiopulmonary exercise test)
Number of subjects: 17
Study 23897911 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nasal prong (SNP)
Number of subjects: 144
Study 23897911 — intervention group
Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 144
Study 20667535 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (testosterone undecanoate, 40 mg/day)
Number of subjects: 200
Study 20667535 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (oral E2 2 mg/day)
Number of subjects: 200
Study 20667535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 19032397 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions
Number of subjects: 92
Study 19032397 — intervention group
Group type: COMPARATOR
Intervention: 17 Gy in two fractions
Number of subjects: 92
Study 19032397 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making process involvement
Number of subjects: 92
Study 17012443 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour magnesium sulfate (MgSO4) therapy
Number of subjects: 200
Study 17012443 — intervention group
Group type: COMPARATOR
Intervention: 24-hour magnesium sulfate (MgSO4) therapy
Number of subjects: 200
Study 17012443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 12-hour and 24-hour magnesium sulfate (MgSO4) therapy
Number of subjects: 200
Study 14592583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment with AFI <5 cm
Number of subjects: 1584
Study 14592583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment with single deepest pool <2 cm
Number of subjects: 1584
Study 14592583 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI <5 cm
Number of subjects: 1584
Study 11078487 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 668
Study 11078487 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 668
Study 8818376 — intervention group
Group type: EXPERIMENTAL
Intervention: Present State Examination (PSE) at baseline
Number of subjects: 0
Study 8818376 — intervention group
Group type: EXPERIMENTAL
Intervention: Present State Examination (PSE) at follow up
Number of subjects: 0
Study 1330942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 16
Study 29545325 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported safety concerns
Number of subjects: 2471
Study 29545325 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported safety incidents
Number of subjects: 2471
Study 29545325 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of patient-reported safety concerns
Number of subjects: 2471
Study 27270968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg)
Number of subjects: 13
Study 27270968 — intervention group
Group type: COMPARATOR
Intervention: PEG3350 (2 × 13.8 g)
Number of subjects: 13
Study 24841020 — intervention group
Group type: COMPARATOR
Intervention: Caudal block with 1 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Number of subjects: 67
Study 24841020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block with 0.3 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Number of subjects: 67
Study 24841020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 23545284 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI of 5‐Fluorouracil (5‐FU), 225 mg/m(2) per day, 7 days per week plus pelvic hyperfractionated radiation (HRT), 45.6 Gy at 1.2 Gy twice daily plus a boost of 9.6 to 14.4 Gy for T3 or T4 cancers (Arm 1)
Number of subjects: 106
Study 23545284 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI of 5‐FU, 225 mg/m(2) per day, Monday to Friday, plus irinotecan, 50 mg/m(2) once weekly × 4, plus pelvic radiation therapy (RT), 45 Gy at 1.8 Gy per day and a boost of 5.4 Gy for T3 and 9 Gy for T4 cancers (Arm 2)
Number of subjects: 106
Study 20004739 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition designed to provide 100% of measured resting energy expenditure (REE)
Number of subjects: 0
Study 20004739 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (140% of estimated energy expenditure)
Number of subjects: 0
Study 20004739 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition designed to provide 100% of measured REE
Number of subjects: 0
Study 18262380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment using sulfadoxine‐pyrimethamine
Number of subjects: 648
Study 18262380 — intervention group
Group type: COMPARATOR
Intervention: Weekly chemoprophylaxis with chloroquine
Number of subjects: 648
Study 18262380 — intervention group
Group type: COMPARATOR
Intervention: Intermittent preventive treatment using three doses of chloroquine
Number of subjects: 648
Study 16573311 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 817
Study 16573311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study 12798153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec (1% chlorhexidine + 0.1% thymol) applied three times over 2 weeks
Number of subjects: 24
Study 12798153 — intervention group
Group type: EXPERIMENTAL
Intervention: EC40 (40% chlorhexidine) applied once or twice over 2 weeks
Number of subjects: 24
Study 10900675 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 0
Study 10900675 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens and combined progestin treatment
Number of subjects: 0
Study 10900675 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 0
Study 8829403 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 40
Study 8829403 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 40
Study 8829403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40
Study 8829403 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 40
Study 8829403 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 40
Study 1503446 — intervention group
Group type: COMPARATOR
Intervention: Cipro alone
Number of subjects: 12
Study 1503446 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (4 x 850 mg tablets taken 5 min before Cipro)
Number of subjects: 12
Study 1503446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (3 x 600 mg tablets taken 5 min before Cipro)
Number of subjects: 12
Study 1503446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Number of subjects: 12
Study 6147695 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining followed by 7 weekly sessions of real-life exposure
Number of subjects: 12
Study 6147695 — intervention group
Group type: COMPARATOR
Intervention: Real-life exposure without breathing retraining
Number of subjects: 12
Study 31497673 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual letter
Number of subjects: 4500
Study 31497673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge-based letter
Number of subjects: 4500
Study 31497673 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (Control)
Number of subjects: 4500
Study 29508273 — intervention group
Group type: EXPERIMENTAL
Intervention: Staple line reinforcement (SLR) using unidirectional absorbable 3/0 V‐Loc 180 sutures
Number of subjects: 920
Study 29508273 — intervention group
Group type: COMPARATOR
Intervention: No staple line reinforcement (Control group)
Number of subjects: 920
Study 26851698 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU)
Number of subjects: 72
Study 26851698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24613367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron administration (510 mg elemental iron as ferumoxytol)
Number of subjects: 39
Study 24613367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 22617226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study 22617226 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 20398947 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy with soft palate phonemes (Group I, N=20)
Number of subjects: 50
Study 20398947 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy with lips and gingival phonemes (Group II, N=20)
Number of subjects: 50
Study 20398947 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy only (Group III, N=10)
Number of subjects: 50
Study 16995844 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP extract
Number of subjects: 18
Study 16995844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12783039 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CRT)
Number of subjects: 22
Study 12783039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 22
Study 12783039 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22
Study 11125604 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive NPO instructions (experimental group, n = 66)
Number of subjects: 122
Study 11125604 — intervention group
Group type: COMPARATOR
Intervention: Usual NPO instructions (control group, n = 56)
Number of subjects: 122
Study 9329204 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked target condition
Number of subjects: 0
Study 9329204 — intervention group
Group type: COMPARATOR
Intervention: Unmarked target condition
Number of subjects: 0
Study 7693422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/m2 orally on days 1 to 14, Methotrexate 40 mg/m2 intravenously on days 1 and 8, Fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 4 weeks for 6 cycles (CMF)
Number of subjects: 761
Study 7693422 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil 600 mg/m2, Epirubicin 50 mg/m2, Cyclophosphamide 600 mg/m2 (FEC), all given intravenously on day 1 for 8 cycles at 3-week intervals
Number of subjects: 761
Study 3517228 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol
Number of subjects: 10
Study 3517228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31774511 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to community health entrepreneurship
Number of subjects: 1211
Study 27215840 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste Lessons with additional experiential learning activities (TLVM)
Number of subjects: 877
Study 27215840 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste Lessons (TL)
Number of subjects: 877
Study 27215840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 877
Study 25926506 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine supplementation (5-177 mg/kg per day) as part of an elemental formula
Number of subjects: 36
Study 23566267 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylcobalamin injection
Number of subjects: 98
Study 23566267 — intervention group
Group type: COMPARATOR
Intervention: Oral methylcobalamin
Number of subjects: 98
Study 23566267 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous 1.0% lidocaine injection
Number of subjects: 98
Study 21307037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive therapy (early routine PCI)
Number of subjects: 1059
Study 21307037 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1059
Study 19098852 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment with peginterferon plus ribavirin for 48-68 weeks (44 weeks after HCV RNA negative)
Number of subjects: 113
Study 19098852 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with peginterferon plus ribavirin for 48 weeks
Number of subjects: 113
Study 16835600 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg elemental iron as ferrous sulfate daily for 6 weeks)
Number of subjects: 20
Study 16835600 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 20